Keywords
How to Cite
Abstract
Transient abnormal myelopoiesis (TAM) is a unique clonal proliferation characterized by immature megakaryoblasts in the fetal liver, peripheral blood, and bone marrow, that occurs in 5-10% of newborn with Down syndrome (DS). Although TAM regresses spontaneously in most patients, approximately 20% of TAM cases result in early death and approximately 20% of survivors develop acute myeloid leukemia (AML) within 4 years. The clinical case of a patient with TAM is described below in order to analyze recent clinical and biological advances, as well as their implications for clinical management.
References
Camargo R, Quezado Magãlhaes I et al. A sensitive and inexpensive high-resolution melting-based testing algorithm for diagnosis of transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.Pediatr Blood Cancer. 2022;69:e29866.
Myoung‐ja Park G, Sotomatsu M, Kaburagi T, Maruyama K, Kobayashi T, Nishi A, Sameshima K, Ohki K, Hayashi Y. Clinical features of 35 Down syndrome patients with transient abnormal myelopoiesis at a single institution. International Journal of Hematology. 2021 113:662–667.
Castro M, Aristizabal Ana M, Aristizabal C, Llanos N, Jaramillo Martha L. Trastornos mieloproliferativos y leucemia en síndrome de Down. Presentación de dos casos clínicos en el período neonatal. Arch Argent Pediatr. 2022;120(2):e89-e92. 4. Watanabe K. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome. Pediatrics International. 2019;61:222–229.
Roberts I. Leukemogenesis in infants and young children with trisomy 21. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):1-8.
Bhatnagar N, Nizery L, Tunsall O, Vyas P, Roberts I. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update. Curr Hematol Malig Rep. 2016;11:333–341.
Telman G, Januszkiewicz-Lewandowska D et al. Why Is Health Care for Children with Down Syndrome So Crucial from the First Days of Life? A Retrospective Cohort Study Emphasized Transient Abnormal Myelopoiesis (TAM) Syndrome at Three Centers. Int JnEnviron Res Public Health. 2022,19,9774.
Giménez V, Romano S, Gutiérrez R, Alba L, Alonso C,Aznar M, Cuello MF, Goldman W, Gorza P, Schuttenberg V, Quatrin M, Costa A. Síndrome mieloproliferativo transitorio en neonato prematuro sin síndrome de Down con trisomía 21 adquirida: reporte de un caso. Hematología;2018;22(3):295-299.
Sas V, Blag C, Zaharie G, Puscas E, Lisencu C, Andronic-Gorcea N, Pasca S, Petrushev B, Chis I, Marian M, Dima D, Teodorescu P, Iluta S, Zdrenghea M, Berindan-Neagoe I, Popa G, Man S, Colita A, Stefan C, Kojima S & Tomuleasa C. Transient leukemia of Down syndrome. Critical Reviews in Clinical Laboratory Sciences. 2019;56(4):247-259.
Roberts I, Alford K, Hall G, Juban G, Richmond H, Norton A et al. GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood. 2013;122:3908–17.
Gamis AS, Alonzo TA, Gerbing RB et al. Natural history of transient myeloproliferative disorder clinicallydiagnosed in Down syndrome neonates: a report fromthe Children’s Oncology Group Study A2971. Blood. 2011;118:6752-6759.
Pennella CL, Cassina TM, Rossi JG, Baialardo EM, Rubio P, Deu MA, Peruzzo L, Guitter MR, Sanchez de La Rosa CG, Alfaro EM, Felice MS. Clonal Myeloproliferative Disorders in Patients with Down Syndrome-Treatment and Outcome Results from an Institution in Argentina. Cancers (Basel). 2022 Jul 5;14(13):3286.
Al-Kasim F, Doyle J, Massey G, Weinstein H, Zipursky A. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome. Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 2002;24:9–13.
Ge Y, Dombkowski AA, LaFiura KM et al. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood. 2006;107:1570–1581.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar